Core Viewpoint - The European Union (EU) has decided to restrict Chinese medical device imports under the International Procurement Instrument (IPI) to counter perceived discrimination against foreign manufacturers in public procurement by Beijing [1][2]. Group 1: EU's Decision and Implications - The EU's decision prohibits Chinese companies from participating in public tender projects for medical devices valued over 5 million euros for the next five years [1]. - The EU China Chamber of Commerce expressed deep disappointment and concern over this decision, stating that it contradicts the principles of open markets and fair competition [1][2]. - The IPI is viewed as a unilateral tool by the EU, which may exacerbate the complexity of EU-China economic relations [1][2]. Group 2: Background and Context - The IPI was introduced in 2022 to allow the EU to investigate non-EU companies and impose restrictions on their market access, particularly targeting emerging economies like China [2]. - The EU initiated a nine-month investigation into public procurement in the Chinese medical device sector under the IPI, marking the first use of this regulation [2]. Group 3: Reactions and Future Negotiations - The EU China Chamber of Commerce highlighted that the EU's pursuit of "market equality" fails to consider the historical context, as European medical device companies have benefited from significant market access in China [3]. - There remains a possibility for an agreement between the EU and China to avoid further measures, with EU Trade Commissioner Valdis Dombrovskis indicating a willingness to negotiate [3]. - The Chinese Ministry of Commerce firmly opposes the EU's discriminatory measures, emphasizing the need for fair competition and warning of potential retaliatory actions [3].

特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无 法看到我们的推送。 据彭博社引述知情人士报道， 欧盟将限制中国医疗器械制造商参与欧盟公共采购合同的资格 。 6月3日，欧盟中国商会注意到媒体当日报道，欧盟成员国依据《国际采购工具》（IPI）批准 对中方采取惩罚性措施的决定，据该决定， 中国企业未来5年将被限制参与价值超过5 0 0万欧 元的欧盟医疗器械公共招标项目 。 对中国投标者扣分 ：在未来的 5 年内，欧盟可能会在评估投标时，对中国供应商的投标进行 额外扣分。 此举源于欧盟于去年4月对中国医疗器械采购展开的调查，并于今年1月 认定中国在医疗器械 采购中存在歧视外国企业的现象 ，后续可能会限制中国参与公开招标。 欧 盟 长 期 以 来 一 直 声 称 ， 中 国 在 推 行 一 些 被 其 认 为 是 " 扭 曲 市 场 " 的 措 施 和 做 法 ， 以 实 施 其"中国制造"政策 ，并实现到2 0 2 5年 中国企业生产"核心医疗器械部件"的国内市场份额达到 8 5% 的目标。对于 高端设备 ，这一目标是 达到7 0% 。 欧 盟 的 报 告 ...